Legislative Talking Points: PSA for HIM Act Jump To Jump To Download PDF The ProblemProstate cancer is the most commonly diagnosed cancer in men.Prostate cancer is the second leading cause of cancer-related death in men.In 2024, an estimated 299,010 men will be diagnosed with prostate cancer and 35,250 men will die from it. After decades of decline, prostate cancer death rates are on the rise: it is estimated that in 2023 over 125,000 more men than in 2017 will be diagnosed with prostate cancer and over 8,000 more men will die from prostate cancer than in 2017. This represents a 78% increase in diagnoses and a 15% rise in the death rate. A man will be diagnosed with prostate cancer every 2 minutes in 2024, and die from it every 15 minutes.African American men are at increased risk for the disease. 1 in 7 African American men will be diagnosed with prostate cancer.African American men are more than 2 times more likely to die from the disease and 1.8 times more likely to be diagnosed with the disease.Veterans who were exposed to herbicides like Agent Orange are at increased risk for developing prostate cancer and are more likely to have an aggressive form of the disease.If caught early, prostate cancer has a five-year survival rate of nearly 100%. However, for late-stage prostate cancer the five-year survival rate is 29%.The economic and social burden of prostate cancer is huge:Prostate cancer is estimated to cost over $8 billion in direct medical expenditures.Men who survive after treatment frequently suffer from side effects, including impotence and incontinenceAccess to Early Screening and DiagnosisCatching prostate cancer early is the key to long term survival.The prostate specific antigen (PSA) test is the current, widely used screening tool for prostate cancer detection.Cost-sharing of any amount can be a barrier to the receipt of needed health care services.Black men and men with a family history of prostate cancer, including a family history of genetic alterations or other cancer associated with increased prostate cancer risk, have a much higher risk of prostate cancer than the general public, making regular screening even more important.H.R. 1826 and S. S.2821 eliminates cost-sharing for PSA testing for men at high risk, ensuring that no one goes without this vital service because of cost.This legislation would give prostate cancer screening parity with other high-value preventive services, like mammography. The AskPlease cosponsor the PSA Screening for HIM Act (H.R.1826), which was introduced by Reps. Larry Bucshon, MD (R-IN) and Yvette Clarke (D-NY). In the Senate, a version hasbeen introduced as S.2821 by Senators Cory Booker (D-NJ) and John Boozman (R-AR). The bill would require that high-risk men (those with a close family history of disease or African American men) have access to prostate cancer screening without any out-of-pocket cost, eliminating unnecessary barriers to early diagnosis and treatment. Download this sheet as a PDF Advocacy Downloadable Materials ZERO Prostate Cancer Summit More for you
The ProblemProstate cancer is the most commonly diagnosed cancer in men.Prostate cancer is the second leading cause of cancer-related death in men.In 2024, an estimated 299,010 men will be diagnosed with prostate cancer and 35,250 men will die from it. After decades of decline, prostate cancer death rates are on the rise: it is estimated that in 2023 over 125,000 more men than in 2017 will be diagnosed with prostate cancer and over 8,000 more men will die from prostate cancer than in 2017. This represents a 78% increase in diagnoses and a 15% rise in the death rate. A man will be diagnosed with prostate cancer every 2 minutes in 2024, and die from it every 15 minutes.African American men are at increased risk for the disease. 1 in 7 African American men will be diagnosed with prostate cancer.African American men are more than 2 times more likely to die from the disease and 1.8 times more likely to be diagnosed with the disease.Veterans who were exposed to herbicides like Agent Orange are at increased risk for developing prostate cancer and are more likely to have an aggressive form of the disease.If caught early, prostate cancer has a five-year survival rate of nearly 100%. However, for late-stage prostate cancer the five-year survival rate is 29%.The economic and social burden of prostate cancer is huge:Prostate cancer is estimated to cost over $8 billion in direct medical expenditures.Men who survive after treatment frequently suffer from side effects, including impotence and incontinenceAccess to Early Screening and DiagnosisCatching prostate cancer early is the key to long term survival.The prostate specific antigen (PSA) test is the current, widely used screening tool for prostate cancer detection.Cost-sharing of any amount can be a barrier to the receipt of needed health care services.Black men and men with a family history of prostate cancer, including a family history of genetic alterations or other cancer associated with increased prostate cancer risk, have a much higher risk of prostate cancer than the general public, making regular screening even more important.H.R. 1826 and S. S.2821 eliminates cost-sharing for PSA testing for men at high risk, ensuring that no one goes without this vital service because of cost.This legislation would give prostate cancer screening parity with other high-value preventive services, like mammography. The AskPlease cosponsor the PSA Screening for HIM Act (H.R.1826), which was introduced by Reps. Larry Bucshon, MD (R-IN) and Yvette Clarke (D-NY). In the Senate, a version hasbeen introduced as S.2821 by Senators Cory Booker (D-NJ) and John Boozman (R-AR). The bill would require that high-risk men (those with a close family history of disease or African American men) have access to prostate cancer screening without any out-of-pocket cost, eliminating unnecessary barriers to early diagnosis and treatment.
